Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis

Franco Locatelli; Michael B. Jordan; Carl E. Allen; Simone Cesaro; Carmelo Rizzari; Anupama Rao; Barbara Degar; Timothy Garrington; Julián Sevilla; M C Putti; Franca Fagioli; Martina Ahlmann; José Luís Dapena; M M Henry; Fabrizio De Benedetti; Alexei A. Grom; G Lapeyre; Philippe Jacqmin; Maria Ballabio; Cristina de Min

doi:10.1056/nejmoa1911326

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Emapalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis. (Funded by NovImmune and the European Commission; NI-0501-04 and NI-0501-05 ClinicalTrials.gov numbers, NCT01818492 and NCT02069899.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Locatelli et al. (2020) studied this question.

synapsesocial.com/papers/69d790061f14cb2b27b8a3d1 https://doi.org/10.1056/nejmoa1911326

View Full Paper

Ask AI

Bookmark

Share

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis

Ask about this paper

Abstract

Discussion

Cite This Study

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading